Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-20

Study Completion Date

2020-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is evaluating the safety and efficacy of the Geneveve Treatment for women experiencing diminished sexual function following vaginal childbirth. Participants will be randomized to either active or sham treatment and followed for 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort

NCT00590590

Vulvodynia

COMPLETED PHASE2

Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products

NCT02534779

Vaginal Diseases

COMPLETED NA

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772

Hiv HSV

COMPLETED PHASE1

Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters

NCT06530186

Vaginal Infection Vaginal Discharge Vaginosis +1 more

NOT_YET_RECRUITING NA

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399

Bacterial Vaginosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Decreased sensation and decreased sexual satisfaction following vaginal childbirth has the potential to negatively impact overall sexual function and quality of life in many women. Previous research by obstetricians and gynecologists (OB/GYNs) found that changes in sexual health post-childbirth are not often discussed between physicians and their patients. One possible reason these discussions are not being initiated by physicians is the lack of an evidence-based treatment other than surgery.

While traditional surgery can be performed to improve sexual function following childbirth, pain at incision lines and scarring can lead to dyspareunia for months following the procedure, and a surgical procedure can be painful and the sutures may cause dense scarring. The post-operative recovery may last up to seven days before a woman can return to work. Resuming intercourse is not recommended for at least six weeks after these invasive surgeries. For the many women who are not good surgical candidates, due to health issues or situational limitations on downtime or their unwillingness to undergo a surgical procedure to improve sexual function, there is no other option.

The Geneveve Treatment offers a simple alternative to traditional surgery using non-ablative radiofrequency (RF) energy as a non-surgical approach to improve sexual function following vaginal childbirth. It induces a mild, controlled reaction in the submucosal tissues that stimulates the body to deposit collagen, thereby remodeling the tissue without causing scarring.

This study is designed to demonstrate that active treatment (i.e., Geneveve Treatment) is superior to the sham treatment for the primary efficacy and safety endpoints.

The active treatment group will receive a treatment dose of 90 J/cm\^2 and the sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2. The participant, the investigator, and all study personnel will be blinded to the assignment for the entire study duration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Sexual Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Geneveve Treatment

Active Treatment

The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Active Treatment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age at time of screening and pre-menopausal
* At least one vaginal delivery (\> 37 completed weeks gestation)
* Sexual dysfunction
* Negative pregnancy test at Screening visit
* Sexually active

Exclusion Criteria

* Currently breastfeeding or recently discontinued breastfeeding
* Medical history of keloid formation, genital fistula, thin recto-vaginal septum or obstetric trauma
* Implantable electrical device
* Medical or immunological condition
* Chronic use of anti-inflammatory drugs
* Current or previous use of local vaginal hormones
* Undergone previous elective surgical or non-invasive procedure(s) at the vaginal introitus

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No